RT Journal Article
SR Electronic
T1 Pharmacokinetics of <sup>99m</sup>Tc-MAA- and <sup>99m</sup>Tc-HSA-Microspheres Used in Preradioembolization Dosimetry: Influence on the Liver–Lung Shunt
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 925
OP 927
DO 10.2967/jnumed.115.169987
VO 57
IS 6
A1 Oliver S. Grosser
A1 Juri Ruf
A1 Dennis Kupitz
A1 Annette Pethe
A1 Gerhard Ulrich
A1 Philipp Genseke
A1 Konrad Mohnike
A1 Maciej Pech
A1 Wolf S. Richter
A1 Jens Ricke
A1 Holger Amthauer
YR 2016
UL http://jnm.snmjournals.org/content/57/6/925.abstract
AB Perfusion scintigraphy using 99mTc-labeled albumin aggregates is mandatory before hepatic radioembolization with 90Y-microspheres. As part of a prospective trial, the intrahepatic and intrapulmonary stability of 2 albumin compounds, 99mTc-MAA (macroaggregated serum albumin [MAA]) and 99mTc-HSA (human serum albumin [HSA]), was assessed. Methods: In 24 patients with metastatic colorectal cancer, biodistribution (liver, lung) and liver–lung shunt (LLS) of both tracers (12 patients each) were assessed by sequential planar scintigraphy (1, 5, and 24 h after injection). Results: Liver uptake of both albumin compounds decreased differently. Although initial LLSs at 1 h after injection were similar in both groups, MAA-LLS increased significantly from 1 (3.9%) to 5 h (7.7%) and 24 h (9.9%) after injection, respectively. HSA-LLS did not change significantly (1 to 5 h), indicating a steady state of pulmonary and intrahepatic degradation. Conclusion: Compared with 99mTc-MAA-microspheres, 99mTc-HSA-microspheres are likely more resistant to degradation over time, allowing a reliable LLS determination even at later time points.